Skip to content

Arrowhead Research ARWR Non-Controlling Interests

Non-Controlling Interests at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10.44M+4.8%
Royalty Pharma logo
Royalty PharmaRPRX
$3.05B-1.7%
Roivant Sciences logo
Roivant SciencesROIV
$765.04M+53.1%
Tenet Healthcare logo
Tenet HealthcareTHC
$1.9B+12.0%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's non-controlling interests.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's non-controlling interests?
Arrowhead Research (ARWR) reported non-controlling interests of -$15.06M in Q1 2026.
How has Arrowhead Research's non-controlling interests changed year-over-year?
Arrowhead Research's non-controlling interests decreased by 1766.0% year-over-year, from $904K to -$15.06M.
What does non-controlling interests mean?
The portion of a subsidiary's equity owned by outside parties rather than the parent company.
How do you interpret non-controlling interests?
Changes reflect the acquisition or divestiture of partial stakes in subsidiaries or the fluctuating performance of those specific entities.
How does non-controlling interests compare across companies?
Common in companies with complex organizational structures or joint ventures in drug development.